1. Contains the same active ingredient as Saxenda: “liraglutide”
Pravobes is an obesity treatment medication that uses liraglutide, the same active ingredient as the GLP-1 receptor agonist Saxenda. Its action and effects are equivalent to Saxenda, suppressing appetite and supporting manageable weight control.
2. “Generic Drug”
Pravobes is a generic version of Saxenda.
Generic drugs are approved, manufactured, and sold as medications containing the same active ingredient, effects, and quality as the original brand-name drug after its patent expires. Their efficacy and safety are thoroughly verified, and they are expected to provide the same effects as the original brand-name drug.
​
3. Priced at ¥11,000 per vial (tax included), making it more affordable to continue
Pravobes is priced at ¥11,000 per vial (tax included), offering savings of approximately ¥3,000 compared to the original Saxenda. This makes it a significantly more economical choice for those considering long-term treatment.
​
​
4. Manufactured by India's leading pharmaceutical company, Cipla
Pravobes is manufactured by Cipla, a major Indian pharmaceutical company established in 1935.
Cipla supplies medicines to over 80 countries and produces high-quality products meeting international approval standards, including those of the US FDA and European EMA.
▶︎ Learn more here
​
​​​​
5. An evolved, smarter injection pen
The Praoves injection pen has evolved to be even easier to use compared to the traditional Saxenda.
The pen body is slimmer, stylish, and lightweight
 
The scale is easy to read, and the dial turns smoothly
 
Bright color tones improve visibility
 
Labels are now uniformly in English, making it easier to handle than the previous Greek labels​​​
 
​
​
6. A medication with stable supply expectations
The previous Saxenda was manufactured in Greece, leading to supply disruptions and price surges due to factors like the Ukraine situation. In contrast, Praoves is manufactured in India, making it less susceptible to geopolitical impacts and offering expectations for stable pricing and supply.